A randomized, placebo-controlled study of amatuximab in combination with pemetrexed and cisplatin (P/C) as front-line therapy for subjects with malignant pleural mesothelioma (MPM).

Authors

Raffit Hassan

Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

Raffit Hassan , Dean Fennell , Arnaud Scherpereel , Anna K. Nowak , Joachim Von Pawel , Silvia Novello , Megan McLaughlin , Kimberly Hoffman , Bruce A. Wallin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma (MPM): An international, multicenter, randomized, double-blind, placebo-controlled phase II study.

First Author: Giorgio V. Scagliotti

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

SWOG S0905: A randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma.

First Author: Anne S. Tsao

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

ATOMIC-Meso: A randomized phase 2/3 trial of ADI-PEG20 or placebo with pemetrexed and cisplatin in patients with argininosuccinate synthetase 1-deficient non-epithelioid mesothelioma.

First Author: Peter Wojciech Szlosarek

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

COMMAND: A phase II randomized, double-blind, placebo-controlled, multicenter study of defactinib as maintenance therapy in subjects with malignant pleural mesothelioma that has not progressed on at least four cycles of pemetrexed/platinum therapy.

First Author: Dean Anthony Fennell